Suvorexant (20mg/15mg and 40mg/30mg) improves sleep for patients with insomnia and reduces the impact of insomnia on patients’ daytime functioning, reports MPR.
“Improvement in sleep onset/maintenance as well as a reduction of the impact of sleep problems on daytime function contribute to the overall improvement observed in ISI total score,” reported William J. Herring, MD, and coauthors, of Merck, in Kenilworth, NJ. “Given that the maximum approved dose is 20mg, the 20mg/15mg data are the most clinically relevant.”
Suvorexant (Belsomra) is an orexin-receptor antagonist that was approved by the Food and Drug Administration (FDA) in 2014 for insomnia treatment. It has been shown to improve sleep onset and maintenance.
